Refining Patient Selection for Biomarker-Directed Immunotherapy

Access Course


As diagnostic and therapeutic advances intersect, there is a significant impact on oncology patient care and increased the use of molecular testing to guide treatment decision-making. While these practices are evidence-based, complex, and incorporated into clinical guidelines, their adoption is fraught with challenges including the multiple companion diagnostic tests associated with immunotherapies. Ask an expert pathologist and oncologist your burning questions as they discuss their strategies for improving molecular testing, which biomarkers to test for, interpreting molecular test results, and how that translates to selecting immunotherapy for patients with solid tumors.


This activity is intended for medical, surgical, radiation oncologists and other healthcare professionals (i.e. oncology nurses, physicians’ assistants, pharmacists, and others) interested/involved in the care of patients with cancer, who are being treated with immunotherapy.


Learning Objectives:

  • Examine the variety of biomarkers associated with immune checkpoint inhibitor therapy
  • Select appropriate, evidence-based testing modalities for patients who are potential candidates for immune checkpoint inhibitor therapy and interpret testing results effectively


Approximate Time to Complete: 60 minutes


Credit Available: June 10, 2020 - February 28, 2021


Developed through a collaboration between SITC and PlatformQ.




Accreditation Council for Continuing Medical Education (MD/DO)
AMA PRA Category 1 Credit(s)™: 1.00